Thornburg Investment Management Inc. acquired a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) in the fourth quarter, Holdings Channel reports. The firm acquired 440,624 shares of the company’s stock, valued at approximately $7,944,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CLBT. Cooper Creek Partners Management LLC bought a new stake in Cellebrite DI during the 3rd quarter valued at about $55,999,000. Granahan Investment Management LLC lifted its holdings in Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after buying an additional 2,411,726 shares in the last quarter. Capital International Investors bought a new stake in Cellebrite DI during the 4th quarter valued at about $41,073,000. Invesco Ltd. lifted its holdings in Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after buying an additional 2,054,644 shares in the last quarter. Finally, Pertento Partners LLP lifted its holdings in Cellebrite DI by 57.8% during the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock valued at $86,131,000 after buying an additional 1,702,574 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.
Cellebrite DI Stock Performance
NASDAQ CLBT opened at $12.84 on Monday. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 45.86, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. The company’s 50-day simple moving average is $13.23 and its two-hundred day simple moving average is $15.03. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98.
Insider Buying and Selling
Analysts Set New Price Targets
CLBT has been the subject of a number of research analyst reports. DA Davidson started coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective for the company. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Finally, Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average target price of $21.40.
Get Our Latest Stock Report on Cellebrite DI
Cellebrite DI Company Profile
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Featured Stories
- Five stocks we like better than Cellebrite DI
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
